View in EDS PDF Full Text

Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.

Saved in:
Bibliographic Details
Title: Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Authors: Van Buren G 2nd; Division of Surgical Oncology, UPMC Pancreatic Cancer Center, Pittsburgh, PA, USA., Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, Moser AJ
Source: Annals of surgical oncology [Ann Surg Oncol] 2013 Nov; Vol. 20 (12), pp. 3787-93. Date of Electronic Publication: 2013 Aug 01.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 23904005
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Van+Buren+G+2nd%22">Van Buren G 2nd</searchLink>; Division of Surgical Oncology, UPMC Pancreatic Cancer Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Ramanathan+RK%22">Ramanathan RK</searchLink><br /><searchLink fieldCode="AU" term="%22Krasinskas+AM%22">Krasinskas AM</searchLink><br /><searchLink fieldCode="AU" term="%22Smith+RP%22">Smith RP</searchLink><br /><searchLink fieldCode="AU" term="%22Abood+GJ%22">Abood GJ</searchLink><br /><searchLink fieldCode="AU" term="%22Bahary+N%22">Bahary N</searchLink><br /><searchLink fieldCode="AU" term="%22Lembersky+BC%22">Lembersky BC</searchLink><br /><searchLink fieldCode="AU" term="%22Shuai+Y%22">Shuai Y</searchLink><br /><searchLink fieldCode="AU" term="%22Potter+DM%22">Potter DM</searchLink><br /><searchLink fieldCode="AU" term="%22Bartlett+DL%22">Bartlett DL</searchLink><br /><searchLink fieldCode="AU" term="%22Zureikat+AH%22">Zureikat AH</searchLink><br /><searchLink fieldCode="AU" term="%22Zeh+HJ%22">Zeh HJ</searchLink><br /><searchLink fieldCode="AU" term="%22Moser+AJ%22">Moser AJ</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229420840%22">Annals of surgical oncology</searchLink> [Ann Surg Oncol] 2013 Nov; Vol. 20 (12), pp. 3787-93. <i>Date of Electronic Publication: </i>2013 Aug 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9420840 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1534-4681 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210689265%22">10689265 </searchLink><i>NLM ISO Abbreviation: </i>Ann Surg Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=23904005
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1245/s10434-013-3161-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3787
    Titles:
      – TitleFull: Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Van Buren G 2nd
      – PersonEntity:
          Name:
            NameFull: Ramanathan RK
      – PersonEntity:
          Name:
            NameFull: Krasinskas AM
      – PersonEntity:
          Name:
            NameFull: Smith RP
      – PersonEntity:
          Name:
            NameFull: Abood GJ
      – PersonEntity:
          Name:
            NameFull: Bahary N
      – PersonEntity:
          Name:
            NameFull: Lembersky BC
      – PersonEntity:
          Name:
            NameFull: Shuai Y
      – PersonEntity:
          Name:
            NameFull: Potter DM
      – PersonEntity:
          Name:
            NameFull: Bartlett DL
      – PersonEntity:
          Name:
            NameFull: Zureikat AH
      – PersonEntity:
          Name:
            NameFull: Zeh HJ
      – PersonEntity:
          Name:
            NameFull: Moser AJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2013 Nov
              Type: published
              Y: 2013
          Identifiers:
            – Type: issn-electronic
              Value: 1534-4681
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Annals of surgical oncology
              Type: main
ResultId 1